• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace Home
  • Fakülteler / Faculties
  • Tıp Fakültesi / Faculty of Medicine
  • View Item
  •   DSpace Home
  • Fakülteler / Faculties
  • Tıp Fakültesi / Faculty of Medicine
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Comparison of stage III mucinous and serous ovarian cancer: a case-control study

Thumbnail
View/Open
document.pdf (810.0Kb)
Date
2018
Author
Ayhan, Ali
Cuylan, Zeliha Fırat
Karabuk, Emine
Oz, Murat
Turan, Ahmet Taner
Meydanli, Mehmet M.
Taskin, Salih
Sari, Mustafa Erkan
Sahin, Hanifi
Ulukent, Suat C.
Akbayir, Ozgur
Gungorduk, Kemal
Gungor, Tayfun
Kose, Mehmet F.
Metadata
Show full item record
Abstract
Background: The purpose of this case-control study was to compare the prognoses of women with stage III mucinous ovarian carcinoma (MOC) who received maximal or optimal cytoreduction followed by paclitaxel plus carboplatin chemotherapy to those of women with stage III serous epithelial ovarian cancer (EOC) treated in the similar manner. Methods: We performed a multicenter, retrospective review to identify patients with stage III MOC at seven gynecologic oncology departments in Turkey. Eighty-one women with MOC were included. Each case was matched to two women with stage III serous EOC in terms of age, tumor grade, substage of disease, and extent of residual disease. Survival estimates were measured using Kaplan-Meier plots. Variables predictive of outcome were analyzed using Cox regression models. Results: With a median follow-up of 54months, the median progression-free survival (PFS) for women with stage III MOC was 18.0months (95% CI; 13.8-22.1, SE: 2.13) compared to 29.0 months (95% CI; 24.04-33.95, SE: 2.52) in the serous group (p = 0.19). The 5-year overall survival rate of the MOC group was significantly lower than that of the serous EOC group (44.9% vs. 66.3%, respectively; p < 0.001). For the entire cohort, presence of multiple peritoneal implants (Hazard ratio [HR] 2.39; 95% confidence interval [CI], 1.38-4.14, p = 0.002) and mucinous histology (HR 2.28; 95% CI, 1.53-3.40, p < 0.001) were identified as independent predictors of decreased OS. Conclusion: Patients with MOC seem to be 2.3 times more likely to die of their tumors when compared to women with serous EOC.
URI
https://ovarianresearch.biomedcentral.com/track/pdf/10.1186/s13048-018-0464-2
http://hdl.handle.net/11727/3130
Collections
  • PubMed İndeksli Yayınlar Koleksiyonu [2404]
  • Scopus İndeksli Yayınlar Koleksiyonu [3081]
  • Tıp Fakültesi / Faculty of Medicine [5169]
  • Wos İndeksli Yayınlar Koleksiyonu [4157]

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV
 

 

Politika
Açık Bilim Politikası
Kullanıcı Rehberi
Başkent Üniversitesi Kütüphanesi
Başkent Üniversitesi


sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeLanguageCategoryThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeLanguageCategory

My Account

LoginRegister

Statistics

View Usage Statistics

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV